Piper Sandler raised the firm’s price target on Bristol Myers (BMY) to $66 from $65 and keeps an Overweight rating on the shares. In the wake of Bristol’s Q1 print, the firm is updating its model, with the bulk of the upward revisions to its sales estimates coming from the company’s legacy business. Regarding the growth portfolio, beyond Cobenfy, Piper is keeping a particularly watchful eye on execution surrounding Sotyktu and Camzyos.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers Chief Medical Officer buys $202K in common stock
- Bristol Myers price target lowered to $47 from $56 at HSBC
- Bristol Myers price target lowered to $52 from $54 at UBS
- Bristol Myers price target raised to $56 from $54 at BofA
- Bristol Myers price target lowered to $53 from $62 at Wells Fargo